Targeting bladder disease where it matters

TARIS Biomedical® is a unique, therapeutically focused urology company developing powerful new treatments for millions of patients suffering from difficult-to-treat bladder diseases. TARIS is advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed.

Year Invested: 2011
Location: Lexington, Mass.

Recent News

April 16, 2018
TARIS® Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine

April 9, 2018
TARIS® Announces Late-Breaking Poster Presentation at American Association of Cancer Research Annual Meeting

April 3, 2018
U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer

Read More News

Associated Team Members

Cary Pfeffer, M.D.